N-ethylamino-tris(hydroxymethyl)methane

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-ethylamino-tris(hydroxymethyl)methane
• 英文别名: 2-(Ethylamino)-2-(hydroxymethyl)-1,3-propanediol；2-(ethylamino)-2-(hydroxymethyl)propane-1,3-diol
• 化学式: C₆H₁₅NO₃
• mdl: MFCD04137961
• 分子量: 149.19
• InChiKey: PAMMITWIWFSAOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  72.7
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-di-tert-butylphenyl phosphorodichloridite 、 N-ethylamino-tris(hydroxymethyl)methane 在 三乙胺 作用下， 以 甲苯 为溶剂， 生成 1-Ethyl-2,8-di(2,4-di-tert-butylphenoxy)-3,7,9-trioxa-1-aza-2,8-diphosphaspiro[4.5]decane
  参考文献：
  名称：

  Substituted 3,7,9-trioxa-1-aza-2,8-diphosphaspiro(4,5)decanes and

  摘要：

  三氧杂-1-氮-2,8-二磷螺[4.5]癸烷的结构式为I，其中R.sub.1和R.sub.2分别为氢、烷基、环烷基、双环烷基、三环烷基或芳基；或当n或m为零时可以是卤素，R.sub.3、R.sub.4、R.sub.5和R.sub.6分别为氢、烷基、芳基烷基或芳基；X和Y分别为--O--、--S--或--NR.sub.16--，其中R.sub.16为烷基、环烷基、烯基、芳基或芳基烷基；W和Z分别为O或S；n、m、o和p分别为零或1，对稳定有机材料抵抗氧气、热和/或光辐射的有害影响具有有效作用。

  公开号：

  US05132426A1

文献信息

• Dendrimers as molecular translocators
  申请人：Goodman Murray

  公开号：US20060216265A1

  公开（公告）日：2006-09-28

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  转运分子包括一种树枝状聚合物和一种生物活性分子。这些转运分子的树枝状聚合物包括至少一个胍基团、至少一个质子化的胍基团、至少一个保护的胍基团、至少一个酰胺基团、至少一个质子化的酰胺基团、至少一个保护的酰胺基团、至少一个脲基团、至少一个质子化的脲基团、至少一个保护的脲基团、至少一个硫脲基团、至少一个质子化的硫脲基团，或至少一个保护的硫脲基团。生物活性分子与树枝状聚合物结合。一种增加药物生物利用度的方法包括将药物与本发明的树枝状聚合物结合。
• [EN] TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES<br/>[FR] COMPOSÉS TRIARYLES POUR LE TRAITEMENT DE MALADIES PD-L1
  申请人：CHEMOCENTRYX INC

  公开号：WO2020232256A1

  公开（公告）日：2020-11-19

  Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  提供了一些作为免疫调节剂有用的化合物。这些化合物具有公式（I），包括立体异构体和其药用盐，其中R1a、R1b、R1c、R1d、R2a、R2b、R3、R3a、R4、R6、R7、R8、A、Z、X1和n如本文所定义。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• Dendrimers as Molecular Translocators
  申请人：Goodman Murray

  公开号：US20080221020A1

  公开（公告）日：2008-09-11

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  运输分子包括一个树状分子和一个生物活性分子。这种运输分子的树状分子包括至少一个鸟氨酸基团，至少一个质子化的鸟氨酸基团，至少一个保护的鸟氨酸基团，至少一个酰胺基团，至少一个质子化的酰胺基团，至少一个保护的酰胺基团，至少一个尿素基团，至少一个质子化的尿素基团，至少一个保护的尿素基团，至少一个硫脲基团，至少一个质子化的硫脲基团，或者至少一个保护的硫脲基团。生物活性分子与树状分子结合。一种增加药物生物利用度的方法包括将药物与本发明的树状分子结合。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang Kenneth He

  公开号：US20080096887A1

  公开（公告）日：2008-04-24

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明公开了式I的化合物和药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4的定义如本文所述。式I的化合物可用于治疗与细胞增殖有关的疾病和/或疾病，例如癌症、炎症、关节炎、血管生成或类似疾病。本发明还公开了包含本发明化合物的制药组合物和使用这些化合物治疗上述疾病的方法。
• NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS
  申请人：HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED

  公开号：US20150073003A1

  公开（公告）日：2015-03-12

  The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.

  本发明提供了新的神经酰胺类似物，其被指定为公式（II）化合物。这些新颖的类似物表现出显著的抗癌作用，因此作为治疗细胞增殖性疾病、神经退行性疾病、与代谢相关的疾病、感染性疾病和免疫相关疾病的药物组合物而提供。本发明还提供了将公式（II）的新的神经酰胺类似物与其他治疗剂组合的组合物和套件。